Merck’s experimental RSV injection lowers infections in infants
The US-based Merck and Co.’s investigational medicine to protect infants from respiratory syncytial virus (RSV) disease has resulted in lowering infections, according to.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
The US-based Merck and Co.’s investigational medicine to protect infants from respiratory syncytial virus (RSV) disease has resulted in lowering infections, according to.